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ARTICLE

Sex Differences in Extrahepatic Outcomes After Antiviral
Treatment for Hepatitis C
Jia Li, PhD1, Stuart C. Gordon, MD2,3, Yueren Zhou, MS1, Joseph A. Boscarino, MD, PhD4, Mark A. Schmidt, PhD5, Yihe G. Daida, PhD6,
Loralee B. Rupp, MS, MBA7, Sheri Trudeau, MPH1 and Mei Lu, PhD1 for the CHeCS Investigators
INTRODUCTION: Despite recognized differences in the rates of cardiovascular and renal disease between men and

women in the general population, studies of the downstream effects of antiviral treatment for hepatitis C
(HCV) have not investigated differences in outcomes based on sex. We analyzed sex differences in risk of
acute coronary syndrome (ACS), end-stage renal disease (ESRD), and ischemic stroke by treatment and
response in a large US-based multisite cohort of HCV patients.
METHODS:

Observation started at the HCV diagnosis date (untreated) or last antiviral treatment start (treated).
Treatment selection bias was addressed using an inverse probability-weighting approach. We estimated
the effect of treatment on the cumulative incidence of outcomes using the Fine-Gray method
(subdistribution hazard ratios [sHR] and 95% confidence intervals [95% CI]). Death was a competing risk.

RESULTS:

Roughly 40% of 15,295 HCV patients were women. After controlling for other risk factors, sustained
virological response (SVR) (interferon-based [IFN] or direct-acting antiviral [DAA]) significantly
reduced risk of all outcomes, particularly among female patients. Female patients who achieved SVR
after IFN-based treatment had significantly lower risk of ACS compared with male patients with SVR
from either treatment type (sHR 0.45 [95% CI 0.35–0.59] vs 0.81 [95% CI 0.69–0.96, for DAA SVR]
and sHR 0.72 [95% 0.62, 0.85, for IFN SVR]). Successful treatment seemed to be most protective
against ESRD; female patients who achieved SVR were at 66%–68% lower risk than untreated patients
(sHR 0.32 [95% CI 0.17–0.60 for DAA SVR] and 0.34 [95% CI 0.20–0.58 for IFN SVR]), whereas men
were at 38%–42% lower risk (sHR 0.62 [95% CI 0.46–0.85 for DAA SVR] and 0.58 [95% CI
0.43–0.76 for IFN SVR]). IFN treatment failure significantly increased risk of all outcomes by
50%–100% among female patients. Compared with no treatment, female patients who experienced
IFN treatment failure were at 63% increased risk of ACS (sHR 1.63 [95% CI 1.35–1.96]), almost twice
the risk of ESRD (sHR 1.95 [95% CI 1.43–2.66]) and 51% increased risk of stroke (sHR 1.49 [95%CI
1.11–2.00]).

DISCUSSION:

SVR reduced the risk of extrahepatic complications, particularly in females. The significantly increased risk
associated with IFN TF in women—a subset who represented roughly 10% of that group—underscores the
importance of prioritizing these patients for DAA treatment irrespective of the fibrosis stage.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B810.
Am J Gastroenterol 2021;116:576–583. https://doi.org/10.14309/ajg.0000000000001095

INTRODUCTION
Chronic infection with hepatitis C (HCV) is associated with increased risk of a number of extrahepatic manifestations, including type 2 diabetes (T2D) and cardiovascular conditions
(1). The Chronic Hepatitis Cohort Study (CHeCS) recently
showed that HCV patients who achieved sustained virological

response (SVR) to antiviral treatment were less likely to develop
T2D (2) and that patients with existing T2D were less likely to
experience acute coronary syndrome (ACS), ischemic stroke, and
end-stage renal disease (ESRD) (3). To date, only a handful of
studies have investigated the impact of SVR on long-term extrahepatic manifestations among HCV patients without T2D; in
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METHODS
Patient population

CHeCS is a retrospective/prospective, observational study that
includes patients from 4 large US health systems—Geisinger
Clinic (Danville, PA), Henry Ford Health System (Detroit, MI),
Kaiser Permanente Hawai’i (Honolulu, HI), and Kaiser Permanente Northwest (Portland, OR). CHeCS follows all guidelines of
the US Department of Health and Human Services regarding
protection of human subjects; study protocols were approved by
the institutional review board at each participating site. The
CHeCS study design has been described previously (14). Brieﬂy,
electronic administrative data and electronic health records for
patients older than or equal to 18 years who received health
services at any study site from January 1, 2006, to December 31,
2016, were used to identify study candidates; eligibility was
conﬁrmed with medical chart abstraction.
For this analysis, the start of the observation period (“index
date”) was deﬁned as the date of last treatment initiation for
treated patients. For untreated patients, the index date was the
dates of HCV diagnosis. Patients were excluded if they had
hepatitis B virus coinfection.
HCV treatment status and response

Detailed antiviral medication data (drug name and start/stop
dates) were collected via chart abstraction. Data on routine HCV
RNA quantiﬁcation tests were obtained via the electronic health
record. Patients with ongoing HCV therapy without suﬃcient
follow-up to assess SVR (deﬁned as undetectable viral RNA loads
$12 weeks post-therapy initiation) were excluded from the
analyses. Patients were classiﬁed into one of 5 treatment status/
outcomes groups—(i) DAA SVR, (ii) DAA TF, (iii) IFN SVR,
(iv) IFN TF, and (v) untreated.
© 2021 by The American College of Gastroenterology

Outcomes of interest

All eligible patients were followed for 3 extrahepatic outcomes:
(i) ACS, (ii) ESRD (15,16), and (iii) ischemic stroke. Outcomes
were deﬁned using the primary International Classiﬁcation of
Diseases (ICD)9-CM/ICD10-CM codes (detailed in Supplementary Table 1, Supplementary Digital Content 1, http://links.
lww.com/AJG/B810). Follow-up continued through the earliest
date of an outcome of interest, patient death, or last administration date. The maximum follow-up was truncated at 5 years.
Patients with a history of any of the outcomes of interest before
index were excluded from the analyses for that outcomes.
Potential confounding factors

Index date demographic information included patient age, sex,
race/ethnicity, type of insurance, and study site. Clinical variables
included body mass index, T2D, hemoglobin A1c laboratory results, antiviral treatment history, HCV genotype, glomerular ﬁltration rate category, Charlson-Deyo comorbidity indices
(calculated from inpatient, outpatient, and claims data for 12
months before the index date) (17), hyperlipidemia, hypertension, ever use of statins, Fibrosis-4 Index (FIB-4—a biomarker
index for liver ﬁbrosis and cirrhosis), and cirrhosis at any time
before index date. Diabetes, hyperlipidemia, and hypertension
within 1 year pre-/post-index date were ascertained using ICD9/
10 codes (see Supplementary Table 1, Supplementary Digital
Content 1, http://links.lww.com/AJG/B810). Pharmacy order
and ﬁll data were used to deﬁne statin use. Owing to the observational
nature of the study, availability of cirrhosis data varied. Roughly 20%
of our sample had liver biopsy/vibration controlled transient elastography data and 60%–70% had laboratory data for calculation of
FIB-4. To overcome this variation, we implemented a hierarchical
classiﬁcation algorithm to identify cirrhosis—(i) decompensated
cirrhosis identiﬁed using our validated Classiﬁcation and Regression
Tree model (18), (ii) “F4” liver biopsy or transient elastography results
.12.5 kPa (19), (iii) FIB-4 .5.88 (20), and (iv) presence of ICD9/10
diagnosis codes for cirrhosis in the electronic health record.
Statistical analysis

To account for confounding due to treatment selection bias, we
used a propensity score approach based on a generalized boosted
model (21), with treatment as the outcome variable and index-date
demographic variables and clinical risk factors as covariates. Propensity scores were calculated for patients in 3 groups—DAA
treated, IFN treated, and never treated—using a generalized
boosted model. Because of the missing data, multiple imputation
by chain equations (22) was implemented under a missing at
random assumption. The propensity score was then averaged
across multiple imputations. Balance of index-date covariates between treated and untreated patients was assessed before and after
inverse propensity weighting (IPW) (23,24). A standardized difference with an absolute value , 0.2 indicates balance between the
groups (25). The treatment eﬀect on risk of each outcome of interest was tested using Fine-Gray subdistribution hazards models
(26), adjusted for IPW. Death was considered as a competing risk.
Given recognized diﬀerences in risk of cardiovascular disease,
we also tested for interactions between treatment status/response
and sex. Signiﬁcant treatment-by-sex interactions (P , 0.05)
were further evaluated to determine whether they were quantitative (diﬀerent in magnitude of eﬀect) or qualitative (diﬀerent in
direction of eﬀect).
The American Journal of GASTROENTEROLOGY
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general, it seems that SVR reduces risk of cardiovascular events,
stroke, and renal disease. These studies have some limitations,
however, in the comparisons between patients by treatment status
(treated or untreated), outcome (SVR or treatment failure [TF]),
or type (interferon-based [IFN] or direct-acting antiviral [DAA]
therapies) (4–6).
To date, only one large study (N . 160,000) has compared the
risk of long-term outcomes across both IFN-based and DAA
treatment, but this study did not distinguish between SVR from
DAA and IFN-based regimens, and the cohort was overwhelmingly (.96%) male (7). There are known sex diﬀerences in
the presentation of HCV, including disease progression, prevalence of extrahepatic manifestations, and response to treatment
(8–10). Similarly, there are well-recognized diﬀerences in risk
proﬁles for cardiovascular and renal disease between men and
women (11–13). As a result, it is imperative that women are
proportionately represented in studies of the relationship between HCV treatment status and cardiovascular outcomes to
allow for conclusions that are generalizable to the wider population. The CHeCS includes a geographically and racially diverse
sample of more than 15,000 HCV patients (40% female) drawn
from 4 large health systems in the United States. Using the
comprehensive electronic health record data, we investigated the
impact of treatment status (untreated, treated with IFN, and
treated with DAA) and outcome (SVR or TF) on risk of incident
ACS, ESRD, and ischemic stroke.
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Figure 1. Flow chart of HCV patient samples for each outcome of interest (ACS, ESRD, and ischemic stroke) by treatment status (untreated, treated with IFN,
and treated with DAA). ACS, acute coronary syndrome; ESRD, end-stage renal disease; DAA, direct-acting antivirals; IFN, interferon-based regimens.

We also conducted several sensitivity analyses. In the ﬁrst
sensitivity analysis, to ensure an appropriate understanding of the
relationship between HCV treatment and the outcomes of interest, we calculated cause-speciﬁc hazards for each outcome
because the eﬀect of a covariate on the cause-speciﬁc hazard for a
particular cause may diﬀer from its eﬀect on the cumulative incidence when competing risks are present (27). Second, to address
possible violations of the proportional hazards assumption with
the above models, we used an alternative approach—the restricted mean survival time (RMST) method—which represents
the area under the survival curve from time 0 to a speciﬁc followup time point; this can be interpreted as the average time until an
event occurs during a deﬁned time period. Use of RMST in the
setting of competing risks and IPW has been described by Calkins
et al. (28); death was considered a competing risk. Conﬁdence
intervals were obtained by 10,000 bootstraps; corresponding Pvalues were calculated by 10,000 permutations. Finally, for our
last sensitivity analysis, we omitted both the Charlson-Deyo
comorbidity score and the indicator for cirrhosis to determine
whether the treatment eﬀect observed in the main analysis
remained consistent despite the omission of important confounders; a robust treatment eﬀect indicates that unobserved
confounding can be disregarded (29).

RESULTS
Figure 1 outlines the number of patients included in the analysis
for each of the outcomes of interest and median follow-up time
and number of events, stratiﬁed by treatment status. Overall,
among 15,295 CHeCS HCV patients, 6,972 (43.6%) were untreated, 4,843 received DAA (SVR 5 91.4%), and 3,467 received
IFN-based treatment (SVR 5 54.2%). Average patient age at
The American Journal of GASTROENTEROLOGY

index was 52 years. Patient characteristics and comorbidities that
are commonly associated with the outcomes of interest were
balanced and within the desired range of standardized diﬀerence
after propensity score weighting. After excluding patients who
had experienced an outcome of interest before the index date,
there were 13,235 patients for the analysis of ACS, 14,349 for
ESRD, and 14,189 for ischemic stroke. For the analysis of ACS,
4,386 patients in the sample were treated with DAA, 4,150 of
whom (94.6%) achieved SVR, 3,207 received IFN-based therapy,
and 1814 of whom (56.6%) achieved SVR. Similar percentages
were observed in the analyses of ESRD and ischemic stroke
(Figure 1). Median follow-up for DAA treated patients was 1.8
years. Table 1 displays details of the analytical samples used for
each outcome of interest by treatment status and sex. Female
patients represented roughly 40% of each analytical sample.
Hazard ratio estimates with fewer than 5 events were deemed
unreliable; as a result, the DAA TF group (n 5 236) was excluded
in the subsequent analyses. Treatment-by-sex interactions were
signiﬁcant for all 3 outcomes (ACS, ESRD, and ischemic stroke;
P , 0.0001); thus, the results for each outcome are presented
stratiﬁed by sex.
Figure 2 displays the adjusted subdistribution hazard ratios
(sHR) for each outcome of interest by treatment status, stratiﬁed
by sex. In general, SVR from either DAA or IFN-based treatment
was associated with reduced risk of outcomes compared with no
treatment. Ischemic stroke was the exception; risk among female
patients with IFN SVR and male patients with DAA SVR trended
lower but was not signiﬁcantly diﬀerent than that among untreated patients. Female patients who achieved SVR after IFNbased treatment had signiﬁcantly lower risk of ACS compared
with male patients with SVR from either treatment type (sHR 0.45
VOLUME 116 | MARCH 2021 www.amjgastro.com
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Treatment type/status

Female (n)

%

Male (n)

%

Total

No event

Death

Event of interest

Incidence rate

1,657

40

2,493

60

4,150

3,944

93

113

13.7

Analytical sample
ACS
DAA SVR
DAA TF

85

36

151

64

236

200

33

3

7.6

IFN SVR

774

43

1,040

57

1,814

1,688

43

83

9.9

IFN TF

518

37

875

63

1,393

1,190

125

78

12.5

Untreated

2,377

42

3,265

58

5,642

4,604

649

389

16.9

Total

5,411

41

7,824

59

13,235

ESRD
DAA SVR

1,829

39

2,816

61

4,645

4,499

120

26

2.8

DAA TF

95

34

181

66

276

234

41

1

2.2

IFN SVR

808

42

1,114

58

1,922

1,861

46

15

1.7

IFN TF

542

37

922

63

1,464

1,286

135

43

6.5

Untreated

2,505

41

3,537

59

6,042

5,114

768

160

6.4

Total

5,779

40

8,570

60

14,349

Ischemic stroke
DAA SVR

1,790

40

2,728

60

4,518

4,379

118

21

2.3

DAA TF

92

34

177

66

269

228

40

1

2.3

IFN SVR

803

42

1,107

58

1,910

1,834

49

27

3.0

IFN TF

541

37

924

63

1,465

1,296

150

19

2.8

Untreated

2,493

41

3,534

59

6,027

5,086

813

128

5.1

Total

5,719

40

8,470

60

14,189

ACS, acute coronary syndrome; DAA, direct-acting antivirals; ESRD, end-stage renal disease; IFN, interferon-based regimens; sHR, subdistribution hazard ratios; SVR,
sustained virological response; TF, treatment failure.

[95% conﬁdence interval {CI} 0.35–0.59] for women vs 0.81 [95%
CI 0.69–0.96, for DAA SVR] and 0.72 [95% CI 0.62–0.85, for IFN
SVR]) for men. Successful treatment also protected against ESRD;
female patients who achieved SVR were at 66%–68% lower risk
than untreated patients (sHR 0.32, 95% CI 0.17–0.60 for DAA
SVR; 0.34, 95% CI 0.20–0.58 for IFN SVR), whereas male patients
were at 38%–42% lower risk (sHR 0.62, 95% CI 0.46–0.85 for
DAA SVR; 0.58, 95% CI 0.43–0.76 for IFN SVR).
There was a signiﬁcant qualitative sex-by-treatment status
interaction for patients who experienced IFN TF. Although IFN
TF was associated with reduced risk of ACS and stroke for male
patients, it was associated with signiﬁcantly increased risk of all
outcomes for female patients. Compared with no treatment, female patients who experienced IFN TF were at 63% increased risk
of ACS (sHR 1.63 [95% CI 1.35–1.96]), almost twice the risk of
ESRD (sHR 1.95 [95% CI 1.43–2.66]), and 51% increased risk of
stroke (sHR 1.49, [95% CI 1.11–2.00). By contrast, male patients
who experience at IFN TF had signiﬁcantly lower risk of ACS and
stroke and increased but not signiﬁcantly higher risk of ESRD
compared with untreated patients.
Figure 3 displays comparisons for female vs male patients for
risk of ACS, ESRD, and ischemic stroke within each treatment
status group. Risks for ACS and ESRD were lower for female
than that for male patients in each treatment category except for
© 2021 by The American College of Gastroenterology

IFN TF; in that category, risk of ACS was 79% higher (sHR 1.79
[95% CI 1.46–2.19) and risk of ESRD was similar (sHR 0.91
[95% CI 0.69–1.20]) in female patients compared with male
patients. By contrast, risk of stroke varied by treatment type.
Female patients who were untreated or achieved SVR after IFNbased treatment had similar risk of stroke to male patients, but
those with DAA SVR had roughly half the risk (sHR 0.42 [95%
CI 0.23–0.76]) and those with IFN TF had almost 3 times the risk
(sHR 2.99 [95%CI 2.04–4.39]) of male patients in the same
treatment groups.
Supplementary Figure 1, Supplementary Digital Content 1,
http://links.lww.com/AJG/B810 displays the results of the
cause-speciﬁc hazard model (a sensitivity analysis). Results
from the cause-speciﬁc model were consistent in magnitude and
signiﬁcance with those of the main analysis, allowing us to
conclude that competing risks did not inﬂuence our observations. Supplementary Figures 2 and 3, Supplementary Digital
Content 1, http://links.lww.com/AJG/B810 detail our second
sensitivity analysis. When comparing RMST at each year, IFN
SVR patients averaged longer time to ACS at 5 years compared
with those who were untreated (RMST ratio 5 1.02; P 5 0.022);
DAA SVR patients also had longer times to ACS, but these
diﬀerences were not statistically signiﬁcant. In sex-stratiﬁed
results, female DAA SVR patients exhibited the longest ACSThe American Journal of GASTROENTEROLOGY
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treatment type/status group
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Figure 2. Fine-Gray sHR for each outcome of interest by treatment type (untreated, treated with IFN, and treated with DAA) and status (SVR or TF), stratified
by sex (orange, female; blue, male). DAA, direct-acting antivirals; IFN, interferon-based regimens; sHR, subdistribution hazard ratios; SVR, sustained
virological response; TF, treatment failure.

free time compared with other groups, starting at year 2, but this
was only statistically signiﬁcant compared with the IFN TF
group. For ESRD, SVR (regardless of treatment type) was associated with statistically signiﬁcantly longer time to ESRD
compared with untreated patients at each year post-treatment.
IFN SVR patients also demonstrated longer ESRD-free time at
years 3, 4, and 5 post-treatment, compared with IFN TF patients.
We observed similar patterns in sex-stratiﬁed analyses. For ischemic stroke, treated patients showed longer time to stroke
compared with untreated patients. In the combined analysis,
this only reached signiﬁcance for DAA SVR patients and IFN TF
patients. In the sex-stratiﬁed analysis, these diﬀerences were
more common among female patients. In contrast to the main
analysis, we did not observe higher risk for the outcomes of
interest among IFN TF patients. This is likely due to proportional hazards assumptions in the Fine-Gray model. In
summary, the RMST results were generally consistent with the
traditional hazard ratio approach; the failure of some RMST
ratios to achieve statistical signiﬁcance is likely because of different model assumptions and power.

DISCUSSION
In a large, racially diverse cohort of HCV patients, we found that
patients who achieved SVR either with DAA or IFN-based
The American Journal of GASTROENTEROLOGY

treatments were at signiﬁcantly reduced risk—20%–50% lower
overall—of ACS, ESRD, and stroke compared with untreated
patients. This ﬁnding contributes to the larger body of research
emphasizing the long-term extrahepatic beneﬁts of successful
antiviral treatment, even after accounting for possible bias in
selection for HCV treatments and for traditional risk factors (e.g.,
T2D, hypertension, hyperlipidemia, and e-glomerular ﬁltration
rate) for cardiovascular and renal disease. Characteristics of different treatment groups were balanced after IPW. (see Supplementary Tables, Supplementary Digital Content 1, http://links.
lww.com/AJG/B810).
We observed a number of quantitative and qualitative interactions between treatment status and sex. Female patients
generally seemed to beneﬁt more from SVR than male patients,
although these diﬀerences did not always reach statistical signiﬁcance. Given the documented sex diﬀerences in both HCV
progression and complications (8–10), as well as overall lower
risk of cardiovascular and renal disease among female patients
(11–13), this observation is perhaps not surprising. We note that
risks also varied by speciﬁc treatment regimen among female
patients who achieved SVR—compared with IFN SVR, DAA
SVR was less protective against ACS and more protective
against stroke. Notably, failure of IFN-based treatment (IFN TF)
was associated with 50%–100% increased risk of all outcomes
VOLUME 116 | MARCH 2021 www.amjgastro.com
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Figure 3. Fine-Gray sHR comparing female patients vs male patients for each outcome of interest within each treatment type (untreated, treated with DAA,
treated with IFN) and status (SVR or TF). DAA, direct-acting antivirals; IFN, interferon-based regimens; sHR, subdistribution hazard ratios; SVR, sustained
virological response; TF, treatment failure.

compared with no treatment, but only among female patients;
IFN TF among male patients, however, was associated with
unchanged or decreased risk of all outcomes of interest. Despite
the replacement of IFN-based treatments by DAA regimens as
standard of care, almost 10% of the women in our “real-world”
cohort fell into the category of IFN TF (living and not having
received DAA therapy) at the time of this analysis. Our results
highlight the importance of identifying these patients with
previous IFN TF and prioritizing them for DAA treatment.
We believe that this is the ﬁrst analysis of the eﬀect of HCV
treatment on extrahepatic outcomes across 2 treatment eras (IFN
and DAA) and by treatment response (SVR or TF), as well as
untreated patients. Our ﬁndings are generally consistent with a
similar study of IFN-treated patients from Taiwan (4) who found
that treatment reduced risk of ACS and stroke by 23% and 38%,
respectively, vs 37% and 31% among our IFN SVR sample. However, that study observed far greater reduction in risk for ESRD
(85% vs the 49% reduction observed in our cohort compared with
untreated patients). This may be because the comparison groups in
this analysis (ever IFN treated vs untreated) diﬀered from our
present analysis (IFN SVR vs untreated and vs IFN TF); it is also
possibly the high rates of chronic kidney disease—including glomerulonephritis, a common extrahepatic manifestation of
HCV—in Taiwan may contribute to these observed diﬀerences
(30). Similarly, our ﬁndings are also generally consistent with those
of a recent study of patients who achieved SVR after IFN-based
treatment (6); this study also found that female patients beneﬁted
more from SVR regarding risk for ACS and ESRD, although differences in how outcomes were deﬁned and diﬀerences in how
non-SVR patients were grouped make direct comparisons not
possible. Hazard ratios for speciﬁc cardiovascular outcomes were
not reported by treatment type and response for the recent large US
Veterans’ Administration study (7), but incidence rates for each
outcome were similar in SVR and non-SVR patients. By contrast,
we observed signiﬁcantly higher risk of these outcomes among
female patients with TF. This diﬀerence may be an artifact of the
primarily male makeup (96%) of the veteran-based cohort.
© 2021 by The American College of Gastroenterology

Our study has some limitations. Although it was designed to
evaluate diﬀerences in the rate of long-term extrahepatic outcomes
associated with chronic HCV by sex and treatment type, it was not
designed to illuminate speciﬁc reasons that may underlie those differences. Previous research has shown that progression of liver ﬁbrosis
and cirrhosis, as well as rates of SVR, vary by sex among patients with
HCV; studies of pre- and post-menopausal women suggest that
hormonal factors may play a part in these diﬀerences (8–10). We
believe it is reasonable to suggest that, coupled with overall lower risk
of cardiovascular and renal disease among women than men (11–13),
such diﬀerences likely underlie the lower rates of poor outcomes observed among female patients who achieved SVR, compared with
male patients. By contrast, there are no long-term studies that can
adequately explain why we observed higher rates of poor outcomes
only among female patients who experienced IFN TF. However, a few
studies from the era of IFN regimens reported the sex of participants
when describing cardiovascular side eﬀects during antiviral treatment
for HCV. For example, in one study, a slightly larger proportion of
female patients experienced complications such as cardiac ischemia
during treatment compared with male patients, although these differences were nonsigniﬁcant in this relatively small sample, which was
also not stratiﬁed by treatment outcome (31); a similar report described that adverse cardiac outcomes from IFN therapy were conﬁned to female patients in a small sample (32). This suggests that
perhaps there are sex diﬀerences in how IFN-based treatment aﬀects
the cardiovascular system. Notably, in our sample, treatment duration
did not vary between IFN SVR and TF patients—suggesting that
neither early discontinuation nor longer duration of treatment are
related to development of the outcomes of interest.
As expected in a real-world study, a portion of our patients
remained untreated with DAA after IFN TF. We recently conducted a survey of a subset of HCV patients in our cohort who
were eligible for DAA treatment. Among roughly 200 patients
who did not initiate DAA therapy, more than one-third were
never referred to a specialist, 12% did not know why they had not
been referred, 11% had more pressing medical issues, 8% reported
not feeling ill, 10% were unable to pay for additional care or lacked
The American Journal of GASTROENTEROLOGY
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transportation, and 16% reported “other reasons.” (33) At one
study site, a pilot outreach program to increase treatment rates
among DAA eligible patients had a low response rate, with patients citing similar reasons to those described above, especially
that they “did not feel sick” or had more pressing medical issues
(data not published).
There are also limitations inherent in the use of observational
data drawn from “real-world” patients. To address missing baseline
data, we used multiple imputation. To control for treatment bias,
propensity score weighting was used; this accounted for diﬀerences
in ﬁbrosis/cirrhosis status as well as Charlson-Deyo comorbidity
scores—which include a number of cardiovascular and renal
conditions, such as history of transient ischemic attacks. We also
performed multiple sensitivity analyses (a cause-speciﬁc hazards
analysis and RMST analysis) to ensure that appropriate conclusions were drawn. The results of all sensitivity analyses were consistent with the main analysis and support our conclusions. A
considerable strength of our study is our analysis of both treatment
status and response—untreated, IFN SVR, IFN TF, and DAA
SVR—stratiﬁed by patient sex. This granularity allowed us to show
a novel eﬀect of IFN TF that was conﬁned only to female patients. A
future analysis will investigate risk factors that may be associated
with poor outcomes in this group.
In summary, we observed that achieving SVR after either IFNbased or DAA regimens reduced risk of ACS, ESRD, and stroke;
female patients largely seemed to beneﬁt more than male patients
within each treatment group. Male patients did not demonstrate
any diﬀerence in beneﬁt between IFN and DAA SVR, whereas
female patients derived more beneﬁt from IFN SVR regarding
ACS and from DAA SVR regarding stroke. Importantly, female
patients who experienced IFN TF were at increased risk of all
outcomes, irrespective of severity of ﬁbrosis or cirrhosis, underscoring the importance of identifying women who have previously failed IFN-based treatment and prioritizing them for
DAA therapy.
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Study Highlights
WHAT IS KNOWN

3 Successful antiviral treatment for HCV may result in reduced
risk for long-term extrahepatic outcomes, but this has not
been examined sufficiently among female patients.

WHAT IS NEW HERE

3 We found that women particularly benefited from successful
treatment regarding reduced risk for ACS, ESRD, and
ischemic stroke compared with patients who did not receive
treatment or those who experienced TF. For stroke, risk was
lower only among female patients who achieved SVR with
DAA therapy. On the other hand, women who experienced
failure of IFN treatment were at higher risk of all outcomes
compared with untreated patients.
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